suPARnostic® is developed to measure the amount of suPAR protein in human blood. If an individual’s suPARnostic® level is very high, there is an increased risk of a negative outcome (e.g. mortality). Appropriate treatment should result in a lowered suPARnostic® level.
suPARnostic® can improve the way seemingly low risk patients are managed – a low suPAR level helps avoid time and resources spent on further investigations, an elevated suPAR level is an indication that the patient is at higher risk of not surviving and it should be further investigated if this is caused by one or more developing diseases.
By measuring an individual’s suPARnostic® level, the patients risk of non-survival will be determined, allowing the doctor to prioritize selection of treatment and monitoring.